Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil
| Autor: | Sangmin Choe, Sang Heon Cho, Sang Koo Lee, Won Seok Yang, Mi Young Bahng, Jai Won Chang, Yook Hwan Noh, Yong Soon Cho, Jong Lyul Ghim, Jung Sik Park, Soon Bae Kim, Hyeong Seok Lim, Kyun-Seop Bae |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Urology Administration Oral Renal function 030226 pharmacology & pharmacy Young Adult 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Humans Medicine Pharmacology (medical) Clinical significance Renal Insufficiency Adverse effect Aged Pharmacology Sulfonamides Kidney Udenafil business.industry Middle Aged Phosphodiesterase 5 Inhibitors medicine.disease Pyrimidines medicine.anatomical_structure Erectile dysfunction Area Under Curve 030220 oncology & carcinogenesis cGMP-specific phosphodiesterase type 5 Female business medicine.drug |
| Zdroj: | The Journal of Clinical Pharmacology. 58:905-912 |
| ISSN: | 0091-2700 |
| Popis: | Udenafil is a phosphodiesterase-5 inhibitor used to treat erectile dysfunction. Although udenafil is not predominantly eliminated by the kidney, renal impairment can alter its secretion/transport pathways. Drug pharmacokinetics and safety must therefore be assessed in subjects with a renal impairment. We investigated the effects of impaired renal function on the pharmacokinetics and safety of a single 100-mg oral dose of udenafil in a single-dose, open-label, parallel-group study of 31 subjects. Cockcroft-Gault creatinine clearance was used to stratify these subjects into healthy controls (>80 mL·min-1 ) and individuals with mild (50 to ≤80 mL·min-1 ), moderate (30 to ≤50 mL·min-1 ), and severe ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text